Natural compounds are a promising source to treat several pathologies. The present study shows the in vivo pharmacological beneficial effect of 4(α-L-rhamnosyloxy)-benzyl isothiocyanate (glucomoringin isothiocyanate; GMG-ITC) obtained from glucomoringin (GMG; 4(α-L-rhamnosyloxy)-benzyl glucosinolate), purified from Moringa oleifera seeds and hydrolyzed by myrosinase enzyme (ß-thioglucoside glucohydrolase; E.C. 220.127.116.11). Cerebral ischemia/reperfusion (CIR) was induced in rats according to a classic model of carotid artery occlusion for a time period of 1 h and the reperfusion time was prolonged for seven days. GMG-ITC (3.5 mg GMG/ml plus 30 μl enzyme/rat; one ml i.p./rat) was administered 15 min after the beginning of ischemia and daily. The results clearly show that GMGITC possesses the capability to counteract the CIR-induced damage reducing TNF-alpha release, I?Balpha cytosolic degradation/NF?Bp65 nuclear translocation, as well as several other direct or indirect markers of inflammation (phospho-ERK p42/44, p-selectin) and oxidative stress (inducible Nitric Oxide Synthase (iNOS), MMP-9). GMG-ITC was shown to exert neuroprotective properties in preventing CIR-induced damage and the related cascade of inflammatory and oxidative mediators that exacerbate the progression of this disease in an experimental rat model. Our results clearly show that the tested phytochemical GMG-ITC possesses the capability to counteract CIR-induced damage.
|Number of pages||14|
|Journal||Journal of Biological Regulators and Homeostatic Agents|
|Publication status||Published - Apr 1 2015|
- Cerebral ischemia/reperfusion
- Moringa oleifera
ASJC Scopus subject areas